Existing drugs could treat chikungunya

August 25, 2017, Agency for Science, Technology and Research (A*STAR), Singapore
The degree of subcutaneous edema during Chikungunya infection (top) and the fingolimod treated mice (bottom) during the peak of joint swelling. Credit: Ref. 1. © Teo et al., American Association for the Advancement of Science

Chikungunya virus (CHIKV) infection could be treated with autoimmune therapies currently used for other conditions, according to research led by A*STAR scientists. 

When transmitted to humans by mosquitoes, CHIKV causes high fever, headaches, and debilitating joint pain. Since 2004 there have been major outbreaks in Africa, Asia, the Caribbean, and South and Central America. There are currently no approved treatments. 

A group led by Lisa F. P. Ng at the A*STAR Singapore Immunology Network (SIgN) demonstrated in 2013 that CD4+ T cells, which mediate immune system responses, play a central role in triggering CHIKV-induced joint swelling. 

To investigate, Ng and Laurent Renia, her colleague at SIgN led the team to transfer CD4+ T cells from both healthy and CHIKV-infected mice into T cell receptor-deficient mice. Only those that received cells from infected donors suffered joint swelling, inflammation and skeletal muscle damage—confirming the key role of these T cells in triggering CHIKV symptoms. 

They then carried out proteome wide screening assays in which CD4+ T cells taken from CHIKV-infected mice were tested against all proteins generated by the CHIKV virus. 

This identified specific segments in two viral proteins, nsP1 and E2, as those that stimulate CD4+ T cell responses to CHIKV. The discovery could be used to help design vaccines against CHIKV and related viruses. 

Applying their findings, the researchers treated groups of CHIKV-infected mice with three clinically-approved T cell suppressive drugs. Tissue samples were then visually assessed by histopathologists. 

Fingolomid, usually used to prevent multiple sclerosis relapses, successfully reduced joint swelling, inflammation and muscle damage in the rodents. It did so both when given as a prophylactic, and following infection as a standard therapeutic treatment. The other two drugs—cyclosporin A and rapamycin—failed to control the disease symptoms in mice. 

Ng and her colleagues stress that the use of fingolomid to treat CHIKV patients with chronic joint pain has yet to be evaluated, but hope their study will lead to further research on whether it and other immunosuppressive drugs could help those with the condition. 

"We were pleased with these findings," says Ng. "They demonstrate our previous theory about the pathogenic role of CD4+ T cells was correct, and suggest existing T cell suppressive drugs could provide viable treatment options for patients." 

The group believes such drugs could also be used to treat inflammation caused by other arthropod-spread viruses that is mediated by virus-specific CD4+ T .

Explore further: First Chikungunya-infected Aedes aegypti mosquitos found in Brazil

More information: Teck-Hui Teo et al. Fingolimod treatment abrogates chikungunya virus–induced arthralgia, Science Translational Medicine (2017). DOI: 10.1126/scitranslmed.aal1333

Related Stories

First Chikungunya-infected Aedes aegypti mosquitos found in Brazil

June 22, 2017
While more than 13,000 cases of Chikungunya viral disease were reported in Brazil in 2015, scientists had never before detected the virus in a captured mosquito in this country. Now, researchers reporting in PLOS Neglected ...

A cell surface protein known to regulate innate immune responses also affects the adaptive immune system

April 15, 2015
Understanding the immune response triggered by the mosquito-borne Chikungunya virus (CHIKV) is key to developing effective treatments. Now, an international team led by A*STAR researchers has shown that a cell surface protein—the ...

Chikungunya test also distinguishes the illness from other mosquito-borne diseases

October 21, 2015
A detection assay that identifies the presence of viral-specific antibodies in patients with Chikungunya virus (CHIKV) has been developed by A*STAR researchers. The technique can also help differentiate between CHIKV and ...

Details of monkey antibodies against chikungunya virus could help to fight the disease in humans

September 24, 2014
Chikungunya fever can cause severe and long-lasting joint pain, with several epidemics affecting multiple continents in the past decade. The illness is caused by chikungunya virus (CHIKV), but there is no effective vaccine ...

Virology: Seeking solutions to viral migration

July 3, 2013
Although seldom fatal, persistent infection by chikungunya virus (CHIKV) afflicts patients with joint pain lasting months or even years. This insect-borne virus has received relatively little scientific attention in the 50 ...

Exploiting the early immune response in Chikungunya fever promises to provide protection

July 4, 2012
(Medical Xpress) -- Chikungunya fever is a viral disease that has re-emerged to cause epidemics in the Pacific region within the last decade. It is caused by the Chikungunya virus (CHIKV), which is transmitted by mosquitoes ...

Recommended for you

Taking the virus out of a mosquito's bite

December 12, 2018
They approach with the telltale sign—a high-pitched whine. It's a warning that you are a mosquito's next meal. But that mosquito might carry a virus, and now the virus is in you. Now, with the help of state-of-the-art technology, ...

Study identifies a key cellular mechanism that triggers pneumonia in humans

December 11, 2018
The relationship between influenza and pneumonia has long been observed by health workers. Its genetic and cellular mechanisms have now been investigated in depth by scientists in a study involving volunteers and conducted ...

Human antibody discovery could save lives from fungal killer

December 11, 2018
A new way to diagnose, treat and protect against stealth fungal infections that claim more than 1.5 million lives per year worldwide has been moved a step closer, according to research published in Nature Communications.

Effect of oral alfacalcidol on clinical outcomes in patients without secondary hyperparathyroidism

December 11, 2018
Treatment with active vitamin D did not decrease cardiovascular events in kidney patients undergoing hemodialysis, according to a research group in Japan. They have reported their research results in the December 11 issue ...

Dialysis patients at risk of progressive brain injury

December 10, 2018
Kidney dialysis can cause short-term 'cerebral stunning' and may be associated with progressive brain injury in those who receive the treatment for many years. For many patients with kidney failure awaiting a kidney transplant ...

Silicosis is on the rise, but is there a therapeutic target?

December 6, 2018
Researchers from the CNRS, the University of Orléans, and the company Artimmune, in collaboration with Turkish clinicians from Atatürk University, have identified a key mechanism of lung inflammation induced by silica exposure, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.